Showing results (51-60 of 180) with videos related to
Sort By:
Pageof 18
Clinicoeconomics and Outcomes Research : CEOR|October 3, 2012
Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across EuropeSilke Walleser, Joshua Ray, Helge Bischoff, et al.Current Medical Research and Opinion|May 27, 2020
Breakthrough cancer pain treatment in Spain: physicians' perception of current opioids utilization and prescriptionFrancisco Villegas Estévez, María Dolores López Alarcón, Alberto Alonso Babarro, et al.Future Oncology (London, England)|June 5, 2015
Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter studyJose Muñoz-Langa, Javier De Castro, Pere Gascó, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
Can this patient be discharged home? Factors associated with at-home death among patients with cancerAlberto Alonso-Babarro, Eduardo Bruera, María Varela-Cerdeira, et al.The Journal of Allergy and Clinical Immunology|February 13, 2007
Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intoleranceAlicia Prieto, Manuel De Barrio, Elena Martín, et al.Thoracic Cancer|September 28, 2020
Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER databaseBegoña Campos-Balea, Javier de Castro Carpeño, Bartomeu Massutí, et al.Clinical Lung Cancer|November 25, 2025
Germline Mutation Analysis and Real-World Impact in a Selected Cohort of Patients with Non-Small Cell Lung Cancer: INHERITY LC StudyMaría Zurera, Juan Carlos Laguna, Laura Mezquita, et al.International Journal of Clinical and Experimental Pathology|June 6, 2015
Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutationsBlanca D López-Ayllón, Javier de Castro-Carpeño, Carlos Rodriguez, et al.BMC Pulmonary Medicine|February 22, 2023
Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in SpainJavier De Castro, Amelia Insa, Roberto Collado-Borrell, et al.Clinical Lung Cancer|June 28, 2011
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trialCesare Gridelli, Jaafar Bennouna, Javier de Castro, et al.Pageof 18